{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T14:43:59Z","timestamp":1790779439220,"version":"4.1.0"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T00:00:00Z","timestamp":1694390400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100019538","name":"Science Fund for Distinguished Young Scholars of Sichuan Province","doi-asserted-by":"publisher","award":["2022NSFSC1165"],"award-info":[{"award-number":["2022NSFSC1165"]}],"id":[{"id":"10.13039\/501100019538","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Purpose:<\/jats:bold> To comprehensively reassess the efficacy and safety of different concentrations of atropine for retarding myopia progression and seek the most appropriate therapeutic concentration for clinical practice.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> We searched PubMed, Cochrane Library, Embase, Chinese Science and Technology Periodicals (VIP) and China National Knowledege Infrastructure (CNKI) from their inception to 23 March 2023, to obtain eligible randomized controlled trials (RCTs) and cohort studies that had atropine in at least one treatment arm and placebo\/no intervention in another arm. We evaluated the risk of bias of the RCTs according to the recommendations of the Cochrane Collaboration for RCTs and quality of cohort studies by the Newcastle\u2012Ottawa Scale. Weighted mean difference (WMD), 95% confidence interval were calculated for meta-analysis. All data analyses were performed using Review Manager 5.3, STATA 12.0 and SPSS 26.0 software.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> A total of 44 studies were included in the meta-analysis. Weighted mean difference (WMD) were 0.73 diopters (D), 0.65 D, 0.35 D per year in refraction progression (<jats:italic>\u03c7<\/jats:italic><jats:sup>2<\/jats:sup> = 14.63, <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup> = 86.3%; <jats:italic>p<\/jats:italic> &amp;lt; 0.001) and \u22120.26\u00a0mm, \u22120.37\u00a0mm, \u22120.11\u00a0mm per year in axial length progression (<jats:italic>\u03c7<\/jats:italic><jats:sup>2<\/jats:sup> = 5.80, <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup> = 65.5%; <jats:italic>p<\/jats:italic> = 0.06) for high (0.5%\u20131%), moderate (0.1%\u20130.25%), and low (0.005%\u20130.05%) dose atropine groups, respectively. Logarithmic dose\u2012response correlations were found between atropine and their effect on change of refraction, axial length, accommodation and photopic pupil diameter. Through these curves, we found that atropine with concentrations \u22640.05% atropine resulted in a residual value of accommodation of more than 5 D and an increase in pupil diameter no more than 3\u00a0mm. Higher doses of atropine resulted in a higher incidence of adverse effects, of which the incidence of photophobia was dose-dependent (<jats:italic>r<\/jats:italic> = 0.477, <jats:italic>p<\/jats:italic> = 0.029).<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Both the efficacy and risk of adverse events for atropine treatment of myopia were mostly dose dependent. Comprehensively considered the myopia control effect and safety of each dose, 0.05% may be the best concentration of atropine to control myopia progression at present, at which myopia is better controlled and the side effects are tolerable.<\/jats:p><jats:p><jats:bold>Systematic Review Registration:<\/jats:bold><jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/#recordDetails<\/jats:ext-link>, CRD42022377705.<\/jats:p>","DOI":"10.3389\/fphar.2023.1227787","type":"journal-article","created":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T12:08:56Z","timestamp":1694434136000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":28,"title":["Comparison of the efficacy and safety of different doses of atropine for myopic control in children: a meta-analysis"],"prefix":"10.3389","volume":"14","author":[{"given":"Peixian","family":"Hou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longqian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoyuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,9,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"191","DOI":"10.16424\/j.cnki.cn32-1807\/r.2021.02.024","article-title":"Effects of different concentrations of atropine in the control of myopia in children","volume":"41","author":"Cai","year":"2021","journal-title":"J. Nant. Univ. Med. Sci."},{"key":"B2","doi-asserted-by":"publisher","first-page":"4274572","DOI":"10.1155\/2021\/4274572","article-title":"Efficacy and adverse effects of atropine for myopia control in children: A meta-analysis of randomised controlled trials","volume":"2021","author":"Chen","year":"2021","journal-title":"J. Ophthalmol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.ophtha.2011.07.031","article-title":"Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1%, and 0.01% doses (atropine for the treatment of myopia 2)","volume":"119","author":"Chia","year":"2012","journal-title":"Ophthalmology"},{"key":"B4","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1136\/bjo.2008.147421","article-title":"Effect of topical atropine on astigmatism","volume":"93","author":"Chia","year":"2009","journal-title":"Br. J. Ophthalmol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.ajo.2013.09.020","article-title":"Atropine for the treatment of childhood myopia: changes after stopping atropine 0.01%, 0.1% and 0.5%","volume":"157","author":"Chia","year":"2014","journal-title":"Am. J. Ophthalmol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.ophtha.2015.07.004","article-title":"Five-year clinical trial on atropine for the treatment of myopia 2: myopia control with atropine 0.01% eyedrops","volume":"123","author":"Chia","year":"2016","journal-title":"Ophthalmology"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1016\/j.ophtha.2006.05.062","article-title":"Atropine for the treatment of childhood myopia","volume":"113","author":"Chua","year":"2006","journal-title":"Ophthalmology"},{"key":"B8","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1089\/jop.2015.0043","article-title":"Atropine 0.01% eyedrops significantly reduce the progression of childhood myopia","volume":"31","author":"Clark","year":"2015","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"B9","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/B978-0-12-179060-8.50009-8","article-title":"CHAPTER 4 - differences between correlation coefficients","volume-title":"Statistical power analysis for the behavioral sciences","author":"Cohen","year":"1977"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1097\/opx.0000000000000037","article-title":"Maximum atropine dose without clinical signs or symptoms","volume":"90","author":"Cooper","year":"2013","journal-title":"Optom. Vis. Sci."},{"key":"B11","doi-asserted-by":"publisher","first-page":"22267","DOI":"10.1038\/s41598-021-01708-2","article-title":"Safety and efficacy of 0.02% and 0.01% atropine on controlling myopia progression: a 2-year clinical trial","volume":"11","author":"Cui","year":"2021","journal-title":"Sci. Rep."},{"key":"B12","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3390\/vision6040073","article-title":"Low-concentration atropine monotherapy vs. Combined with MiSight 1 Day contact lenses for myopia management","volume":"6","author":"Erdinest","year":"2022","journal-title":"Vis. (Basel)"},{"key":"B13","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1089\/jop.2009.0135","article-title":"Prevention of myopia onset with 0.025% atropine in premyopic children","volume":"26","author":"Fang","year":"2010","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1037\/a0024338","article-title":"Effect size estimates: current use, calculations, and interpretation","volume":"141","author":"Fritz","year":"2012","journal-title":"J. Exp. Psychol. Gen."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1136\/bjophthalmol-2019-315440","article-title":"Effect of low-dose atropine on myopia progression, pupil diameter and accommodative amplitude: low-dose atropine and myopia progression","volume":"104","author":"Fu","year":"2020","journal-title":"Br. J. Ophthalmol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"756398","DOI":"10.3389\/fmed.2021.756398","article-title":"Varying dose of atropine in slowing myopia progression in children over different follow-up periods by meta-analysis","volume":"8","author":"Gan","year":"2021","journal-title":"Front. Med. (Lausanne)"},{"key":"B17","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1001\/jamaophthalmol.2017.1091","article-title":"Efficacy and adverse effects of atropine in childhood myopia: A meta-analysis","volume":"135","author":"Gong","year":"2017","journal-title":"JAMA Ophthalmol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.ophtha.2021.10.016","article-title":"Efficacy and safety of 8 atropine concentrations for myopia control in children: A network meta-analysis","volume":"129","author":"Ha","year":"2022","journal-title":"Ophthalmology"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.3760\/cma.j.issn.0376-2491.2019.24.005","article-title":"Combination with different anticholinergic eyedrops for the treatment of children myopia","volume":"99","author":"Han","year":"2019","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"B20","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1167\/iovs.62.5.6","article-title":"IMI prevention of myopia and its progression","volume":"62","author":"Jonas","year":"2021","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.4103\/ijo.IJO_165_18","article-title":"Allergic reactions to atropine eye drops for retardation of progressive myopia in children","volume":"66","author":"Kothari","year":"2018","journal-title":"Indian J. Ophthalmol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s40123-019-00217-w","article-title":"Atropine 0.01% eye drops for myopia control in American children: A multiethnic sample across three US sites","volume":"8","author":"Larkin","year":"2019","journal-title":"Ophthalmol. Ther."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1111\/ceo.14148","article-title":"Low-concentration atropine eyedrops for myopia control in a multi-racial cohort of Australian children: A randomised clinical trial","volume":"50","author":"Lee","year":"2022","journal-title":"Clin. Exp. Ophthalmol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1097\/opx.0000000000000178","article-title":"Atropine slows myopia progression more in Asian than white children by meta-analysis","volume":"91","author":"Li","year":"2014","journal-title":"Optom. Vis. Sci."},{"key":"B25","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1111\/opo.12052","article-title":"How does atropine exert its anti-myopia effects?","volume":"33","author":"McBrien","year":"2013","journal-title":"Ophthalmic & physiological Opt."},{"key":"B26","doi-asserted-by":"publisher","first-page":"e0281816","DOI":"10.1371\/journal.pone.0281816","article-title":"A comparison of myopia control in European children and adolescents with defocus incorporated multiple segments (DIMS) spectacles, atropine, and combined DIMS\/atropine","volume":"18","author":"Nucci","year":"2023","journal-title":"PLoS One"},{"key":"B27","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ Clin. Res. ed.)"},{"key":"B28","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1167\/iovs.18-25221","article-title":"Prevention and management of myopia and myopic pathology","volume":"60","author":"Saw","year":"2019","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/j.ophtha.2021.01.026","article-title":"Atropine for the treatment of childhood myopia in India: multicentric randomized trial","volume":"128","author":"Saxena","year":"2021","journal-title":"Ophthalmology"},{"key":"B30","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1089\/jop.1999.15.85","article-title":"Effects of different concentrations of atropine on controlling myopia in myopic children","volume":"15","author":"Shih","year":"1999","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"B31","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1034\/j.1600-0420.2001.790304.x","article-title":"An intervention trial on efficacy of atropine and multi-focal glasses in controlling myopic progression","volume":"79","author":"Shih","year":"2001","journal-title":"Acta Ophthalmol. Scand."},{"key":"B32","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"B33","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.ophtha.2008.10.020","article-title":"Atropine for the treatment of childhood myopia: effect on myopia progression after cessation of atropine","volume":"116","author":"Tong","year":"2009","journal-title":"Ophthalmology"},{"key":"B34","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1097\/APO.0000000000000414","article-title":"A meta-analysis assessing change in pupillary diameter, accommodative amplitude, and efficacy of atropine for myopia control","volume":"10","author":"Tran","year":"2021","journal-title":"Asia Pac J. Ophthalmol. (Phila)."},{"key":"B35","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1097\/icl.0000000000000677","article-title":"Biological mechanisms of atropine control of myopia","volume":"46","author":"Upadhyay","year":"2020","journal-title":"Eye contact lens"},{"key":"B36","doi-asserted-by":"publisher","first-page":"e7371","DOI":"10.1097\/md.0000000000007371","article-title":"Atropine 0.5% eyedrops for the treatment of children with low myopia: A randomized controlled trial","volume":"96","author":"Wang","year":"2017","journal-title":"Med. Baltim."},{"key":"B37","article-title":"The newcastle-ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses","volume":"7","author":"Wells","year":"2014","journal-title":"Ott. Health Res. Inst. Web site"},{"key":"B38","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ophtha.2018.05.029","article-title":"Low-concentration atropine for myopia progression (LAMP) study: A randomized, double-blinded, placebo-controlled trial of 0.05%, 0.025%, and 0.01% atropine eye drops in myopia control","volume":"126","author":"Yam","year":"2019","journal-title":"Ophthalmology"},{"key":"B39","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/j.ophtha.2019.12.011","article-title":"Two-year clinical trial of the low-concentration atropine for myopia progression (LAMP) study: phase 2 report","volume":"127","author":"Yam","year":"2020","journal-title":"Ophthalmology"},{"key":"B40","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.ophtha.2021.10.002","article-title":"Three-year clinical trial of low-concentration atropine for myopia progression (LAMP) study: continued versus washout: phase 3 report","volume":"129","author":"Yam","year":"2022","journal-title":"Ophthalmology"},{"key":"B41","first-page":"180","article-title":"Comparison of the effect of atropine and cyclopentolate on myopia","volume":"21","author":"Yen","year":"1989","journal-title":"Ann. Ophthalmol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"388","DOI":"10.3980\/j.issn.1672-5123.2022.3.07","article-title":"Safety and efficacy of 0.005% Atropine eye drops on myopia progression in children with low myopia","volume":"22","author":"Zhao","year":"2022","journal-title":"Int. Eye Sci."},{"key":"B43","doi-asserted-by":"publisher","first-page":"533","DOI":"10.3969\/j.issn.1006-8422.2020.06.013","article-title":"Effect of 0.01% Atropine eye drops on controlling myopia and accommodation functionin adolescents","volume":"28","author":"Zheng","year":"2020","journal-title":"J. Clin. Ophthalmol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1080\/13510002.2021.1976568","article-title":"N-acetyl cysteine ameliorates aortic fibrosis by promoting M2 macrophage polarization in aging mice","volume":"42","author":"Zhu","year":"2021","journal-title":"Chin. J. Sch. Health"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1227787\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T12:46:39Z","timestamp":1694436399000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1227787\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,11]]},"references-count":44,"alternative-id":["10.3389\/fphar.2023.1227787"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1227787","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,11]]},"article-number":"1227787"}}